This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mullamitha, S. A. Search for Related Content PubMed PubMed Citation Articles by Mullamitha, S. A.

Phase I Evaluation of a Fully Human Anti–_v Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors

Authors' Affiliations: ¹ Cancer Research UK and ² Department of Medical Physics, Christie Hospital, Withington; ³ Imaging Science and Biomedical Engineering, University of Manchester, Manchester, United Kingdom; and ⁴ Department of Clinical Trial Management, ⁵ Oncology Discovery Research, ⁶ Clinical Pharmacology, and ⁷ Oncology Clinical Research and Development, Centocor Research and Development, Inc., Malvern, Pennsylvania

Requests for reprints: Gordon Jayson, Department of Medical Oncology, Christie Hospital, Wilmslow Road, Withington, Manchester M20 4BX, United Kingdom. Phone: 44-161-446-3606; Fax: 44-161-446-8565; E-mail: Gordon.Jayson{at}christie-tr.nwest.nhs.uk.

Purpose: A fully human monoclonal antibody to anti–_v integrins (CNTO 95) has been shown to inhibit angiogenesis and tumor growth in preclinical studies. We assessed the safety and pharmacokinetics of CNTO 95 in patients with advanced refractory solid tumors.

Experimental Design: In this phase I trial, CNTO 95 (0.1, 0.3, 1.0, 3.0, and 10.0 mg/kg) was infused on days 0, 28, 35, and 42, and clinical assessments, dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), and [¹⁸F]-2-fluorodeoxyglucose positron emission tomography (FDG-PET) were done. Patients achieving stable disease or better were eligible for extended dosing every 3 weeks for up to 12 months.

Results: Among the 24 enrolled patients, CNTO 95 was associated with one episode of grade III and four episodes of grade II infusion-related fever (all responded to acetaminophen). Of the six patients who received extended dosing, one patient (10.0 mg/kg), with cutaneous angiosarcoma, had a 9-month partial response. Pre- and post-treatment lesion biopsies confirmed tumor cell _v integrin expression, as well as CNTO 95 penetration of the tumor and localization to tumor cells in association with reduced bcl-2 expression. A lesion in one patient (10.0 mg/kg) with stable ovarian carcinosarcoma was no longer detectable by FDG-PET by day 49. Exposure to CNTO 95 seemed to increase in a greater-than-dose-proportional manner; dose-dependent mean half-life ranged from 0.26 to 6.7 days.

Conclusions: CNTO 95 was generally well tolerated. Six patients received extended therapy, including one patient with a prolonged response. Biopsy data confirmed tumor localization and pharmacodynamic activity.

This article has been cited by other articles:

				S. Ning, J. A. Nemeth, R. L. Hanson, K. Forsythe, and S. J. Knox Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo Mol. Cancer Ther., June 1, 2008; 7(6): 1569 - 1578. [Abstract] [Full Text] [PDF]

				J. P.B. O'Connor, G. C. Jayson, A. Jackson, D. Ghiorghiu, B. M. Carrington, C. J. Rose, S. J. Mills, R. Swindell, C. Roberts, C. L. Mitchell, et al. Enhancing Fraction Predicts Clinical Outcome following First-Line Chemotherapy in Patients with Epithelial Ovarian Carcinoma Clin. Cancer Res., October 15, 2007; 13(20): 6130 - 6135. [Abstract] [Full Text] [PDF]

				A. Jackson, J. P.B. O'Connor, G. J.M. Parker, and G. C. Jayson Imaging Tumor Vascular Heterogeneity and Angiogenesis using Dynamic Contrast-Enhanced Magnetic Resonance Imaging Clin. Cancer Res., June 15, 2007; 13(12): 3449 - 3459. [Abstract] [Full Text] [PDF]